Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: Long-term follow-up

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

• Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy via openalex
• doi:10.1007/978-88-470-2186-0_7 via openalex
• doi:10.1002/1097-0142(19850715)56:2<403::aid-cncr2820560233>3.0.co;2-x via openalex
• doi:10.1016/s0029-7844(97)00297-4 via openalex
• doi:10.1097/00004347-198609000-00005 via openalex
• doi:10.1016/j.maturitas.2004.08.008 via openalex
• doi:10.1016/j.contraception.2004.02.004 via openalex
• W2338305153 via openalex
• doi:10.1016/j.contraception.2004.12.004 via openalex
• W7073660035 via openalex
• doi:10.1067/mob.2002.122130 via openalex
• doi:10.1016/s0140-6736(00)04615-8 via openalex
• doi:10.2165/00128413-200112870-00010 via openalex
• doi:10.1007/978-3-319-46334-6 via openalex
• doi:10.1067/mob.2003.346 via openalex
• doi:10.1016/0014-2964(66)90001-6 via openalex
• doi:10.1016/j.contraception.2004.12.021 via openalex

Cited by (16)

• The efficacy of levonorgestrel intrauterine device, medroxyprogesterone acetate, and norethisterone acetate in the treatment of endometrial hyperplasia without atypia 2024
• Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: A prospective, open-label, randomized controlled phase II study 2023
• Effect of the Levonorgestrel-Releasing Intrauterine System on the Uterine Artery, Uterine Volume, and Endometrium in Endometrial Hyperplasia without Atypia 2019
• Erratum: HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia 2016
• HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia 2016
• Response to “A new approach to the management of ovarian endometrioma to prevent tissue damage and recurrence” 2016
• Efficacy of the Levonorgestrel-Releasing Intrauterine Device as an Alternative to Oral Progesterone in the Management of Endometrial Hyperplasia without Atypia 2014
• Levonorgestrel-Releasing Intrauterine Device Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia 2014
• Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases 2013
• Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia 2011
• The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women 2010
• Non-contraceptive applications of the levonorgestrel intrauterine system 2010
• Best Practice & Research Clinical Obstetrics and Gynaecology 2009
• Intrauterine progestins, progesterone antagonists, and receptor modulators: a review of gynecologic applications 2009
• Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system 2008
• Bleeding with menopausal hormone therapy 2008

Source provenance

openalex

last seen: 2026-05-11T06:41:50.100108+00:00